Navigation Links
Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
Date:5/27/2008

a flavanol-rich cocoa drink on vascular function in diabetic adults was investigated. In the first part of this study, medically-treated adults with type 2 diabetes -- a population known to have impaired blood vessel function, putting them at higher risk for cardiovascular disease -- drank a well-characterized and standardized cocoa beverage made using the Mars Cocoapro(R) process that contained different flavanol levels, ranging from 75 to 963 milligrams, and had their blood vessel function measured for several hours following consumption. The researchers found a positive correlation between the flavanol dose consumed and immediate improvements in FMD (flow mediated dilation, a measure of vessel health, i.e. the ability of a vessel to relax).

In a subsequent controlled 30-day, double-masked clinical trial, adults with established diabetes who were medically controlled, drank either a flavanol-containing cocoa beverage or a low-flavanol control three times a day. The cocoa beverages contained either 25 milligrams of cocoa flavanols (control) or 321 milligrams of cocoa flavanols (treatment) and were matched for calories, nutrients and other cocoa compounds such as theobromine and caffeine

Beyond the immediate improvements in FMD following flavanol consumption, participants experienced sustained improvements in blood vessel function upon consuming the flavanol-containing cocoa over a period of 30 days (30 percent increase in FMD between day one and 30).

"We were pleasantly surprised by the magnitude of impact of cocoa flavanols on vascular function in these diabetic adults," said Mars, Incorporated Chief Science Officer Harold Schmitz, PhD. "If a dietary intervention with cocoa flavanols can produce such profound, sustained improvements in vascular function on-top of standard medication in a population with increased risk for cardiovascular diseases, the implications with regard to health and quality of life could be remarkable."

While this
'/>"/>

SOURCE Mars, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
9. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Calif. , Aug. 3, 2015  Isis ... today announced a strategic collaboration to discover and ... diseases. The new collaboration builds on a broad ... AstraZeneca,s strategic approach in these therapeutic areas using ... to extend use of its antisense technology to ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 /PRNewswire/ ... needs of customers who are increasingly mobile, increasingly connected, ... support a growing variety of customer interaction channels and ... of technology, including social media. According ... of the over the counter (OTC) segment in a ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to ... University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative ... Africa. , A cooperative agreement awarded by the U.S. Agency for International ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato ... new program “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive ... healthcare organizations with access to the tactics, techniques and practices required to design ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... - When given alongside radiation therapy for head and ... to reduce the debilitating side effect of xerostomia, according ... Anderson Cancer Center and Fudan University Shanghai Cancer Center. ... , reported findings from the first randomized controlled trial ...
... press release is available in French . , ... metastasis has been identified by a team of researchers led by ... Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused ... of the body, most often to the bones and lungs. These ...
... Norwegians, the investigators found that alcohol consumption was associated ... from coronary artery disease. For men, the fully ... CI 0.39 - 0.69) when comparing subjects reporting more ... or rarely drinking; for women, it was 0.62 (0.3-.23). ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... , THURSDAY, Nov. 10 (HealthDay News) -- ,Heavy ... according to a new study. It also confirmed ... and schizophrenia. Methamphetamine and other amphetamine-type stimulants are ... worldwide. In this study, researchers at the Centre ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay ... livers are typically subject to a mandatory six-month "dry-out" ... Unfortunately, many of the sickest of these patients fail ... that earlier transplants can dramatically improve survival odds in ...
Cached Medicine News:Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:New target identified to stop the spread of breast cancer 2Health News:Flexible rack systems sort molecules 2Health News:Heavy Meth Use Linked to Schizophrenia 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 3
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: